Skip to main content

Table 3 Trial-level association of all included studies (Spearman’s rho)

From: Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings

Treatment effect of surrogate endpoint

Treatment effect of true endpoint

No. of trials

rs

95% CI

ΔORR

HR of OS

112

0.462

0.303, 0.597

ΔORR

HR of PFS

114

0.764

0.675, 0.831

HR of PFS

HR of OS

138

0.584

0.462, 0.684